Atea Pharmaceuticals, Inc. (AVIR) Revenue History
Annual and quarterly revenue from 2018 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
AVIR Revenue Analysis (2018–2024)
As of February 28, 2026, Atea Pharmaceuticals, Inc. (AVIR) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, AVIR's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $351.4 million in 2021.
When compared to Healthcare sector peers including BNTX (+3.7% YoY), MRNA (-56.1% YoY), and CDTX (-100.0% YoY). Compare AVIR vs BNTX →
Peer Comparison
Compare AVIR's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AVIRCurrent | $0 | - | - | - | |
| BNTX | $2.8B | +3.7% | +90.9% | -47.8% | |
| MRNA | $3.2B | -56.1% | +121.3% | -123.3% | |
| CDTX | $1M | -100.0% | -42.9% | -13811.9% | |
| SCNI | $658,000 | +303.9% | - | -1312.8% | |
| NVAX | $1.1B | +64.7% | +118.8% | 40.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $-83,367,000 | - | $-192,950,000 | - |
| 2023 | $0 | - | $-70,090,000 | - | $-164,162,000 | - |
| 2022 | $0 | -100.0% | $-62,390,000 | - | $-130,650,000 | - |
| 2021 | $351.4M | +622.5% | $184.2M | 52.4% | $138.4M | 39.4% |
| 2020 | $48.6M | - | $10.6M | 21.8% | $-11,030,000 | -22.7% |
| 2019 | $0 | - | $-17,000 | - | $-14,608,000 | - |
| 2018 | $0 | - | $-17,000 | - | $-9,477,000 | - |
See AVIR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AVIR Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare AVIR vs AGIO
See how AVIR stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is AVIR's revenue growth accelerating or slowing?
AVIR TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is AVIR's long-term revenue growth rate?
Atea Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is AVIR's revenue distributed by segment?
AVIR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2024 are available for download. Segment mix reveals concentration and diversification trends.